Private Wealth Partners LLC Boosts Stock Holdings in Stryker Co. (NYSE:SYK)

Private Wealth Partners LLC increased its stake in Stryker Co. (NYSE:SYK) by 2.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 35,487 shares of the medical technology company’s stock after acquiring an additional 908 shares during the quarter. Stryker comprises approximately 0.9% of Private Wealth Partners LLC’s investment portfolio, making the stock its 29th biggest position. Private Wealth Partners LLC’s holdings in Stryker were worth $10,627,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA increased its holdings in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. HBC Financial Services PLLC acquired a new stake in Stryker during the 4th quarter worth $37,000. Bourgeon Capital Management LLC acquired a new stake in Stryker during the 4th quarter worth $37,000. Operose Advisors LLC boosted its stake in Stryker by 308.6% during the 3rd quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after purchasing an additional 108 shares during the last quarter. Finally, Venturi Wealth Management LLC boosted its stake in Stryker by 97.1% during the 4th quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock worth $41,000 after purchasing an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.5 %

NYSE SYK traded down $1.54 during trading hours on Friday, reaching $335.61. The company had a trading volume of 1,063,790 shares, compared to its average volume of 1,108,426. The stock has a 50-day moving average of $348.88 and a 200 day moving average of $315.16. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $127.69 billion, a P/E ratio of 40.68, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.00 earnings per share. As a group, research analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.95%. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The disclosure for this sale can be found here. Insiders have sold 212,109 shares of company stock worth $72,845,768 over the last three months. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Evercore ISI lifted their target price on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and boosted their price target for the company from $315.00 to $360.00 in a research report on Wednesday, January 31st. Roth Mkm boosted their price target on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Citigroup boosted their price target on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $340.67.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.